Tyler Earnings: Healthy Environment Drives a Strong Quarter All Around
Wide-moat Tyler TYL reported second-quarter results that were ahead of our estimates for both revenue and profitability despite the accelerating software as a service transition, which tends to mute both measures. Management believes the demand environment remains at healthy levels at or above prepandemic levels, and we concur. Additionally, the firm tweaked 2023 guidance, with the revenue range narrowed around the same midpoint, while non-GAAP EPS was moved $0.10 higher at the midpoint. Changes, therefore, were modest within our model, which in turn holds our fair value estimate stable at $475 per share. We continue to see federal stimulus funds as supporting the healthy environment and see consistent growth and margin expansion over time. We believe Tyler is the clear leader for municipal software needs and therefore continue to view shares as attractive.
The pipeline remains healthy, and state budgets are in good shape; this helps drive all revenue lines to be stronger than we anticipated. Total revenue grew 8% year over year to $504 million, compared with FactSet consensus of $491 million. Excluding COVID-19-related revenue from the NIC acquisition, revenue grew 10% year over year. Importantly, SaaS revenue was up 20% year over year as reported. We see the most notable strength in Subscriptions, Maintenance, and Hardware relative to our model.
SaaS deals drove 82% of annual contract value, versus 87% last quarter and 74% a year ago. We expect this to inch up to more than 95% over the next several years, as the public sector is clearly onboard with SaaS consumption at this point. Non-GAAP annual recurring revenue, or ARR, was $1.657 billion, up 11% year over year; bookings were flat year over year against a difficult comparison; and backlog increased 3% year over year. SaaS ARR grew 20% year over year. Further, about a third of the installed base has converted to SaaS from on-premises, so the runway remains long. We see these forward-looking indicators as healthy.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.